NeuroPace, Inc. (NPCE)
NASDAQ: NPCE · Real-Time Price · USD
13.83
-0.32 (-2.26%)
Mar 3, 2026, 4:00 PM EST - Market closed
NeuroPace Revenue
In the year 2025, NeuroPace had annual revenue of $99.99M with 25.13% growth. NeuroPace had revenue of $26.59M in the quarter ending December 31, 2025, with 23.86% growth.
Revenue (ttm)
$99.99M
Revenue Growth
+25.13%
P/S Ratio
4.61
Revenue / Employee
$478,402
Employees
209
Market Cap
460.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 99.99M | 20.08M | 25.13% |
| Dec 31, 2024 | 79.91M | 14.49M | 22.14% |
| Dec 31, 2023 | 65.42M | 19.90M | 43.72% |
| Dec 31, 2022 | 45.52M | 337.00K | 0.75% |
| Dec 31, 2021 | 45.18M | 4.05M | 9.83% |
| Dec 31, 2020 | 41.14M | 4.17M | 11.27% |
| Dec 31, 2019 | 36.97M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Varex Imaging | 854.40M |
| Orthofix Medical | 822.31M |
| Bioventus | 563.83M |
| OrthoPediatrics | 236.35M |
| Cerus | 206.13M |
| Cytek Biosciences | 201.49M |
| Pacific Biosciences of California | 160.01M |
| Beta Bionics | 100.25M |
NPCE News
- 8 hours ago - NeuroPace, Inc. (NPCE) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 13 hours ago - NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook - Business Wire
- 11 days ago - NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026 - Business Wire
- 6 weeks ago - NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook - Business Wire
- 2 months ago - NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy - Business Wire
- 3 months ago - NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy - Business Wire